MEI Pharma announced its first LTC purchase, sparking a rally for one of the oldest and well-established crypto coins.

San Diego-based MEI Pharma (NASDAQ:MEIP) has acquired 929,548 Litecoin (CRYPTO: LTC) tokens, becoming the first U.S.-listed ...

Analysts told Decrypt though ETF approval rumors are adding to optimism, it’s MEI Pharma’s buy-in last month that is really ...

EDT MEI Pharma (MEIP) files to sell 25.3M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, ...

GSR, crypto’s capital markets partner, today announced an investment and strategic partnership with MEI Pharma, Inc. (NASDAQ:MEIP) (“MEI”), in which it will serve as both strategic advisor and digital ...

An update from MEI Pharma ( (MEIP) ) is now available.

Consensus from 7 of the American Biotechs analysts is that MEI Pharma is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$8.4m in 2024.

MEI Pharma had cash and cash equivalents of $36.2 million as of March 31, 2018. It was anticipating at first that its cash would be enough until the 1st half of its calendar 2019.

Shares of MEI Pharma were last trading up 17% at $1.95, with a 52-week trading range of $1.23 to $2.28.

MEI Pharma has a 52-week trading range of $1.87 to $13.98. Keep in mind that Monday was the day that the 52-week low was hit, and shares had been at $6.30 on Friday’s closing bell.